SCHEMBL31396604

SCHEMBL31396604

Cc1ccc(S(=O)(=O)n2cc(-c3ccc4oc(C)nc4c3)c3cc(Br)cnc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.52
GCK P35557 1/20 0.38
L3MBTL1 Q9Y468 4/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 4/20 0.36
XBP1 P17861 1/20 0.36
ENPP3 O14638 1/20 0.36
ENPP1 P22413 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PTPN2 P17706 2/20 0.36
PTPN1 P18031 2/20 0.36
PTPN5 P54829 2/20 0.36
HPGD P15428 2/20 0.36
ALOX12 P18054 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30280399 0.87 PTPN11 (0.50) PTPN11L3MBTL1MAPTALDH1A1ENPP3
SCHEMBL31396642 0.86 PTPN11 (0.53) PTPN11GCKL3MBTL1MAPTALDH1A1
SCHEMBL31396616 0.85 PTPN11 (0.53) PTPN11L3MBTL1GAAMAPTALDH1A1
SCHEMBL31396576 0.85 PTPN11 (0.49) PTPN11L3MBTL1MAPTALDH1A1ENPP3
SCHEMBL31344454 0.81 PTPN11 (0.50) PTPN11L3MBTL1MAPTALDH1A1ENPP3
SCHEMBL1516664 0.80 PTPN11 (0.52) PTPN11L3MBTL1MAPTALDH1A1ENPP3
SCHEMBL720190 0.80 PTPN11 (0.49) PTPN11L3MBTL1MAPTALDH1A1ENPP3
SCHEMBL31396553 0.80 PTPN11 (0.54) PTPN11L3MBTL1GAAMAPTALDH1A1
SCHEMBL31396517 0.80 PTPN11 (0.49) PTPN11L3MBTL1MAPTALDH1A1KDM4E
SCHEMBL23247251 0.80 L3MBTL1 (0.58) PTPN11L3MBTL1GAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH PTPN11 80/4885GCK 2595/4885L3MBTL1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.